Ra Medical beat expectations on most important metric, says Piper Jaffray
Ra Medical Systems reported Q1 results that beat the Street on the sales, which is the most important metric, Piper Jaffray analyst Matt O'Brien tells investors in a research note. Management did not provide guidance for Q2 or the year and is communicating to investors to look at Q3 as the proper measuring stick for its sales force realignment, which is not overly surprising as these changes always take longer than expected, adds the analyst. He finds it important that Ra Medical Systems has fixed its manufacturing problems and can now make as much product as demand it can generate. O'Brien believes risk-tolerant investors "should take a close look at the story" and reiterates an Overweight rating on Ra Medical, despite reducing his price target to $9 from $11.